Lipigon Pharmaceuticals
0.34 SEK +2.72%Be the first to follow this company
Lipigon Pharmaceuticals operates in the pharmaceutical industry. The company specializes in the research and development of various drug candidates. The product portfolio is broad and includes drugs for rare diseases. These are mainly treatments for diseases caused by disorders in the body's handling of fats. In addition to the main business, service and associated ancillary services are also offered. Lipigon Pharmaceuticals operates worldwide, with the largest presence in the Nordic market.
Revenue
16.41M
EBIT %
-75.38 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
LPGO
Daily low / high price
0.306 / 0.34
SEK
Market cap
42.98M SEK
Turnover
43.34K SEK
Volume
134K
Financial calendar
General meeting
2024-05-23
Interim report
2024-05-28
Interim report
2024-08-27
Interim report
2024-11-21
Annual report
2025-02-19
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Nordnet Pensionsförsäkring AB | 9.6 % | 9.6 % |
Försäkringsaktiebolaget Avanza Pension | 7.9 % | 7.9 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Lipigon: Vd Stefan K. Nilsson ökar sitt aktieinnehav ytterligare
Lipigon publicerar årsredovisning för 2023
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools